Labcorp Holdings Inc. (LH) Gross Margin: 27.79%
Is Labcorp Holdings Inc.’s gross margin high or low?
Labcorp Holdings Inc.'s gross margin of 27.79% is 11% below its 5-year average of 31.16%, near the low end of its 5-year range (26.75%–38.01%).
As of Sunday, June 14, 2026. 1.78% above its 12-month average of 27.30%.
LH Gross Margin Chart
LH Average Gross Margin Chart
LH Current vs Average Gross Margin Chart
LH Gross Margin Metrics
GROSS MARGIN
27.79%
GROSS MARGIN AVG TTM
27.30%
GROSS MARGIN AVG 3Y
28.39%
GROSS MARGIN AVG 5Y
31.16%
GROSS MARGIN AVG 10Y
31.16%
GROSS MARGIN AVG 15Y
33.77%
GROSS MARGIN AVG 20Y
35.71%
CURRENT VS TTM AVG
+1.78%
CURRENT VS 3Y AVG
-2.10%
CURRENT VS 5Y AVG
-10.82%
CURRENT VS 10Y AVG
-10.82%
CURRENT VS 15Y AVG
-17.71%
CURRENT VS 20Y AVG
-22.17%
LH Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Labcorp Holdings Inc. (LH) | $21.83B | 27.79% | 27.30% | 28.39% | 31.16% |
| Mettler-Toledo International Inc. (MTD) | $22.86B | 57.79% | 57.84% | 57.54% | 57.23% |
| BioNTech SE (BNTX) | $22.90B | 73.26% | 78.98% | 81.24% | 82.89% |
| United Therapeutics Corporation (UTHR) | $23.17B | 86.58% | 88.58% | 89.63% | 90.66% |
| Waters Corporation (WAT) | $23.17B | 55.02% | 58.60% | 58.69% | 58.45% |
| Moderna, Inc. (MRNA) | $19.80B | -13.89% | 54.80% | 53.09% | 65.45% |
| Veeva Systems Inc. (VEEV) | $25.92B | 74.95% | 75.03% | 73.28% | 73.00% |
| Hologic, Inc. (HOLX) | $16.97B | 52.82% | 58.14% | 57.33% | 59.28% |
| DexCom, Inc. (DXCM) | $29.08B | 61.84% | 60.23% | 62.09% | 63.91% |
| Biogen Inc. (BIIB) | $29.53B | 69.77% | 73.30% | 74.61% | 77.63% |
Gross Margin Analysis
Gross Margin
27.8%
(Revenue - COGS) / Revenue
Labcorp Holdings Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Labcorp Holdings Inc. Gross Margin FAQ
- What is the gross margin for Labcorp Holdings Inc. (LH)?
- The gross margin for LH stock is 27.79%.
- Is Labcorp Holdings Inc.'s gross margin high or low?
- Labcorp Holdings Inc.'s gross margin of 27.79% is 11% below its 5-year average of 31.16%, near the low end of its 5-year range (26.75%–38.01%).
- What is the TTM average gross margin for Labcorp Holdings Inc. (LH)?
- The TTM average gross margin for LH stock is 27.30%.
- What is the 3Y average gross margin for Labcorp Holdings Inc. (LH)?
- The 3Y average gross margin for LH stock is 28.39%.
- What is the 5Y average gross margin for Labcorp Holdings Inc. (LH)?
- The 5Y average gross margin for LH stock is 31.16%.
- What is the 10Y average gross margin for Labcorp Holdings Inc. (LH)?
- The 10Y average gross margin for LH stock is 31.16%.
- What is the 15Y average gross margin for Labcorp Holdings Inc. (LH)?
- The 15Y average gross margin for LH stock is 33.77%.
- What is the 20Y average gross margin for Labcorp Holdings Inc. (LH)?
- The 20Y average gross margin for LH stock is 35.71%.
Labcorp Holdings Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 26.75% |
| 2024-12-31 | 27.86% |
| 2023-12-31 | 27.67% |
| 2022-12-31 | 31.26% |
| 2021-12-31 | 38.01% |
| 2020-12-31 | 35.43% |
| 2019-12-31 | 28.15% |
| 2018-12-31 | 28.03% |
| 2017-12-31 | 33.18% |
| 2016-12-31 | 32.99% |
| 2015-12-31 | 33.45% |
| 2014-12-31 | 36.65% |
| 2013-12-31 | 38.28% |
| 2012-12-31 | 39.67% |
| 2011-12-31 | 41.04% |
| 2010-12-31 | 41.92% |
| 2009-12-31 | 41.98% |
| 2008-12-31 | 41.59% |
| 2007-12-31 | 41.57% |
| 2006-12-31 | 42.59% |
| 2005-12-31 | 41.78% |
| 2004-12-31 | 41.80% |
| 2003-12-31 | 41.66% |
| 2002-12-31 | 42.34% |
| 2001-12-31 | 42.08% |
| 2000-12-31 | 42.86% |
| 1999-12-31 | 40.17% |
| 1998-12-31 | 38.25% |
| 1997-12-31 | 32.57% |
| 1996-12-31 | 29.78% |
Related Metrics
About Labcorp Holdings Inc.
Labcorp Holdings, Inc. offers vital diagnostic laboratory services, enabling medical professionals, healthcare facilities, pharmaceutical firms, scientific investigators, and patients to make well-informed and confident choices. The company commenced operations on April 16, 2024, and its main office is situated in Burlington, NC.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Adam H. Schechter